Neutralizing anti--interferon gamma (IFN-γ) autoantibodies have been reported to cause adult-onset immunodeficiency, resulting in severe opportunistic infections due to intracellular pathogens such as fungi and mycobacteria [@bib1], [@bib2], [@bib3]. Disseminated infections caused by nontuberculous mycobacteria (NTM) involve various organs, primarily the lungs, lymph nodes and skin [@bib1], [@bib2], [@bib4]. To our knowledge, however, hepatobiliary NTM infection with obstructive jaundice has never been reported.

A 74-year-old Japanese man sought care at a previous hospital with a 2-month history of general fatigue and lymphadenopathy. The findings at physical examination were unremarkable except for cervical and axillary lymphadenopathy. A chest computed tomography revealed right supraclavicular, mandibular and bilateral axillary lymphadenopathy and bilateral psoas abscess. Culture of biopsy samples of his right supraclavicular and axillary lymph nodes was positive for *Mycobacterium avium,* indicating disseminated *M. avium* disease. He was treated by antimycobacterial therapy with rifampicin (450 mg per day), ethambutol (750 mg per day) and clarithromycin (800 mg per day). Standard antimycobacterial therapy for over 2 years improved his clinical symptoms and lesions.

One month later, he was admitted to our hospital with portal hepatic and right axillary lymphadenopathy, which were positive for *M. avium.* Total bilirubin level was 6.1 mg/dL, and direct-reacting bilirubin level was 3.9 mg/dL. Immunoglobulin levels were within the normal range (IgG, 1555 mg/dL; IgM, 126 mg/dL; IgA, 348 mg/dL). HIV antibody testing was negative, and his CD4/CD8 lymphocyte counts were within normal ranges. Epstein-Barr virus nuclear antigen, viral capsid antigen IgG 2.6 and viral capsid antigen IgM 0.9 were detected by the enzyme immunoassay method. The positive control for QuantiFERON-TB Gold (QFT-3G) was undetectable. We detected a high titre of serum neutralizing anti--IFN-γ autoantibodies by enzyme-linked immunosorbent assay (patient, 50.85 EU; control, 25.49 EU). These antibodies are also potent inhibitors of IFN-γ--stimulated signal transducer and activator of transcription 1 (STAT1) phosphorylation in leukocytes using a previously described method [@bib2] ([Fig. 1](#fig1){ref-type="fig"}(A)). Briefly, recombinant human IFN-γ was added to Jurkat cells inoculated with serum. After the cells were permeabilized, anti--phospho-STAT1 antibodies were conjugated, and the cells were subsequently analysed by flow cytometry. According to the results of this assay, anti--IFN-γ autoantibodies were proved to have a neutralizing effect in this patient.Fig. 1(A) Analysis of IFN-γ--induced STAT1 phosphorylation in leukocytes by flow cytometry. IFN-γ (10 ng/mL) increased p-STAT1 in healthy controls but did not increase p-STAT1 in patient. Recombinant human IFN-γ was added to Jurkat cells inoculated with serum. After cells were permeabilized, anti-pSTAT1 antibodies were conjugated, and cells were subsequently analysed by flow cytometry, revealing that anti--IFN-γ autoantibodies worked as neutralizing antibodies in this patient. (B) MRCP showing intrahepatic bile duct dilation (white arrow). (C) Endoscopic retrograde cholangiopancreatography showing hilar bile duct stricture (black arrow). IFN-γ, interferon gamma; MRCP, magnetic resonance cholangiopancreatography; p-STAT1, phosphorylated signal transducer and activator of transcription 1; STAT1, signal transducer and activator of transcription 1.Fig. 1

After the detection of anti--IFN-γ autoantibodies, we continued antimycobacterial chemotherapy. After 1 year of therapy, he sought care for jaundice and systemic pruritus. Contrast-enhanced abdominal computed tomography and magnetic resonance cholangiopancreatography ([Fig. 1](#fig1){ref-type="fig"}(B)) and hilar bile duct stricture by endoscopic retrograde cholangiopancreatography (ERCP) ([Fig. 1](#fig1){ref-type="fig"}(C)) revealed intrahepatic bile duct dilation. PCR and culture from bile was positive for *M. avium,* whereas sputum, blood and bone marrow results were negative, resulting in a diagnosis of hepatobiliary *M. avium* infection. In addition to continuing the same antimycobacterial regimen, a stent was placed in the bile duct after insertion of an endoscopic nasobiliary drainage tube. His symptoms and laboratory findings improved, with no relapse observed during 2 years of treatment.

HIV-associated cholangiopathy due to biliary obstruction resulting from a benign stricture of the biliary tract has been reported [@bib5]. Patients with HIV-associated cholangiopathy showed near-normal bilirubin concentrations, with only a few patients requiring a procedure to resolve the biliary obstruction [@bib6], suggesting the pathogenesis of cholangiopathy in our patient was likely not HIV associated, while neutralizing anti--IFN-γ autoantibodies could cause similar immunodeficiency in advanced HIV infection.

To our knowledge, non--HIV-associated hepatobiliary NTM infection has never been reported. Although adjunct therapy with rituximab was considered in our patient [@bib7], stent placement during ERCP had successfully improved patient outcome without disease relapse. Hepatobiliary *M. avium* infection should be considered in the differential diagnosis of jaundiced patients with neutralizing anti--IFN-γ autoantibodies, even those receiving antimycobacterial therapy for disseminated *M. avium* disease [@bib8]. In addition to antimycobacterial therapy, biliary decompression by stent placement using the ERCP procedure may be an effective treatment option.
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